Wen-Jun Tu1, Qiang Liu2, Jian-Lei Cao1, Sheng-Jie Zhao1, Xian-Wei Zeng1, Ai-Jun Deng1. 1. From the Institute of Radiation Medicine, China Academy of Medical Science and Peking Union Medical College, Tianjin (W.-J.T., Q.L.); Department of Neurology, China Rehabilitation Research Center, Beijing (W.-J.T., S.-J.Z.); Department of Cardiology, Zhongnan Hospital of Wuhan University, China (J.-L.C.); and Department of Neurosurgery, Affiliated Hospital of Weifang Medical College, China (X.-W.Z., A.-J.D.). 2. From the Institute of Radiation Medicine, China Academy of Medical Science and Peking Union Medical College, Tianjin (W.-J.T., Q.L.); Department of Neurology, China Rehabilitation Research Center, Beijing (W.-J.T., S.-J.Z.); Department of Cardiology, Zhongnan Hospital of Wuhan University, China (J.-L.C.); and Department of Neurosurgery, Affiliated Hospital of Weifang Medical College, China (X.-W.Z., A.-J.D.). liuqiang_cams@163.com wfzwxin@126.com.
Abstract
BACKGROUND AND PURPOSE: The aim of the study was to evaluate the association of the measurement of serum γ-glutamyl transferase (GGT) concentrations at admission with 1-year all-cause or cardiovascular disease (CVD) mortality in patients with acute ischemic stroke. METHODS: This prospective, multicenter cohort study was conducted in 4 stroke centers in China. Baseline GGT measurements were tested. The relationship of GGT to the risk of death from all-cause or CVD was examined among 1-year follow-up patients. RESULTS: We recorded results from 5912 patients with stroke. In those patients, 51.0% were men, and the median age was 61 years. In both men and women, high GGT was significantly associated with total mortality from all-cause or CVD (P<0.001). The elevated GGT revealed adjusted hazard ratios (95% confidence interval) of 3.03 (1.99-4.54) and 3.24 (2.14-4.92) for mortality from all-cause and CVD, respectively. With an area under the curve of 0.69 (95% confidence interval, 0.66-0.73), GGT showed a significantly greater discriminatory ability to predict all-cause mortality as compared with others factors. GGT improved the National Institutes of Health Stroke Scale score (area under the curve of the combined model, 0.75 [95% confidence interval, 0.73-0.78]; P<0.01). CONCLUSIONS: This study demonstrates that GGT is independently associated with all-cause and CVD mortality in patients with ischemic stroke.
BACKGROUND AND PURPOSE: The aim of the study was to evaluate the association of the measurement of serum γ-glutamyl transferase (GGT) concentrations at admission with 1-year all-cause or cardiovascular disease (CVD) mortality in patients with acute ischemic stroke. METHODS: This prospective, multicenter cohort study was conducted in 4 stroke centers in China. Baseline GGT measurements were tested. The relationship of GGT to the risk of death from all-cause or CVD was examined among 1-year follow-up patients. RESULTS: We recorded results from 5912 patients with stroke. In those patients, 51.0% were men, and the median age was 61 years. In both men and women, high GGT was significantly associated with total mortality from all-cause or CVD (P<0.001). The elevated GGT revealed adjusted hazard ratios (95% confidence interval) of 3.03 (1.99-4.54) and 3.24 (2.14-4.92) for mortality from all-cause and CVD, respectively. With an area under the curve of 0.69 (95% confidence interval, 0.66-0.73), GGT showed a significantly greater discriminatory ability to predict all-cause mortality as compared with others factors. GGT improved the National Institutes of Health Stroke Scale score (area under the curve of the combined model, 0.75 [95% confidence interval, 0.73-0.78]; P<0.01). CONCLUSIONS: This study demonstrates that GGT is independently associated with all-cause and CVD mortality in patients with ischemic stroke.